RESOURCE CENTER
Latest Publications
Hard-earned Insights That Help Drug Manufacturers Achieve Their Growth, Compliance, & Profitability Objectives
VA Labeler Code Enforcement
VA Labeler Code Enforcement: Why Pharmaceutical Manufacturers Should Prepare Now If your pharmaceutical company relies on a third-party dealer to access the U.S. Department of Veterans Affairs (VA) market, recent activity from the VA Federal Supply Schedule (FSS)...
U.S. Pharmaceutical Tariffs Expand to Generic Drugs
U.S. Pharmaceutical Tariffs Expand to Generic Drugs: What Manufacturers Need to Know When Prescription Analytics first examined pharmaceutical tariff policy in 2025, no pharma-specific framework had been finalized. Since then, the policy has advanced, with a branded...
CMS Confirms Q2 2026 ASP Reporting Requirements for Reasonable Assumptions and BFSF Documentation
CMS Confirms Q2 2026 ASP Reporting Requirements for Reasonable Assumptions and BFSF Documentation CMS has provided updated guidance on the new Average Sales Price (ASP) reporting requirements related to reasonable assumptions and, where applicable, bona fide service...
Are You Considering Lowering Your WAC?
ARE YOU CONSIDERING LOWERING YOUR WAC? What Pharma Manufacturers Need to Know Before Making the Move A WAC decrease can look simple on paper. For pharmaceutical manufacturers, lowering the Wholesale Acquisition Cost may seem like a straightforward pricing decision to...
Medicaid rebate processing trends pharma manufacturers should watch in 2026
Medicaid Rebate Processing Trends Pharma Manufacturers Should Watch As Medicaid enrollment volume stabilizes following the pandemic, Medicaid rebate processing challenges continue to create financial exposure for pharmaceutical manufacturers. These trends are largely...
VA Federal Supply Schedule Contract Terms May Extend to 20 Years
VA Federal Supply Schedule Contract Terms May Extend to 20 Years For pharmaceutical manufacturers with VA Federal Supply Schedule (FSS) agreements, the Department of Veterans Affairs (VA) recently announced a structural change that could affect long-term planning,...
CMS Delays New Q1 2026 ASP Reporting Requirements
CMS Delays New Q1 2026 ASP Reporting Requirements CMS has announced that the new ASP reporting requirements tied to bona fide service fee certifications and reasonable assumptions will be waived for the first sales quarter of 2026 due to implementation delays. As a...
What the 12-Digit NDC Means for Government Pricing, Rebates, and Reporting
What the 12-Digit NDC Means for Government Pricing, Rebates, and Reporting The FDA recently finalized a rule transitioning National Drug Codes (NDCs) from the current 10 and 11 digit formats to a standardized 12-digit NDC structure (6-4-2). Implementation begins March...
CMS 2026 ASP Reporting Update: Reasonable Assumptions Form Due April 30
CMS 2026 ASP Reporting Update: Reasonable Assumptions Form Due April 30 Under the 2026 CMS Final Rule, pharmaceutical manufacturers face a new compliance requirement: beginning with Q1 2026 ASP reporting, manufacturers must submit a Reasonable Assumptions Form...